

PATENT ASSIGNMENT

Electronic Version v1.1  
Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PATHWAY THERAPEUTICS LIMITED	11/03/2010

RECEIVING PARTY DATA

Name:	PATHWAY THERAPEUTICS INC.
Street Address:	409 Illinois Street
City:	San Francisco
State/Country:	CALIFORNIA
Postal Code:	94158

PROPERTY NUMBERS Total: 10

Property Type	Number
Application Number:	61164359
Application Number:	61223687
Application Number:	61247454
Application Number:	12748251
Application Number:	61164358
Application Number:	61223684
Application Number:	61247448
Application Number:	61318195
Application Number:	12831128
Application Number:	61387836

CORRESPONDENCE DATA

Fax Number: (858)314-1150

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 858-314-1200

Email: scgenua@jonesday.com

501351781

PATENT  
REEL: 025375 FRAME: 0721

CH \$400.00 61164359

Correspondent Name: JONES DAY  
Address Line 1: 222 East 41st Street  
Address Line 2: Sandra Genua  
Address Line 4: New York, NEW YORK 10017-6702

ATTORNEY DOCKET NUMBER:	322610-600001
-------------------------	---------------

NAME OF SUBMITTER:	Sandra Genua
--------------------	--------------

Total Attachments: 2 source=Assignment_Pathway_Therapeutics_Limited_to_Pathway_Therapeutics_Inc#page1.tif source=Assignment_Pathway_Therapeutics_Limited_to_Pathway_Therapeutics_Inc#page2.tif
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## ASSIGNMENT

WHEREAS, **PATHWAY THERAPEUTICS LIMITED**, a New Zealand Company, located at Level 10, 70 Symonds Street, Auckland, New Zealand, ASSIGNOR, is an owner of right, title, and interest in the inventions contained in the patent applications listed in **Table 1**, attached;

and WHEREAS, **PATHWAY THERAPEUTICS INC.**, a Delaware company, having a place of business at 409 Illinois Street, San Francisco, CA 94158, ASSIGNEE, is desirous of obtaining ASSIGNOR'S entire right, title and interest in, to and under the said inventions and the said applications:

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, the said ASSIGNOR, has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, its entire right, title and interest in, to and under the said inventions, and the said United States provisional applications and all applications claiming priority thereto under 35 U.S.C. §119(e) and divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said inventions in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said inventions in any country or countries foreign to the United States and all extensions, renewals and reissues thereof.

AND ASSIGNOR HEREBY authorizes and requests the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants and agrees that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith.

AND ASSIGNOR HEREBY further covenants and agrees that ASSIGNOR will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting said inventions, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said inventions in all countries.

IN TESTIMONY WHEREOF, the undersigned Officer has affixed his or her signature.

Name: Julie Cherrington  
Title: CEO of Pathway Therapeutics Ltd.

Julie Cherrington Nov 3, 2010  
Signature Date

STATE OF CALIFORNIA )

COUNTY OF San Francisco )

On 3 Nov, 2010 before me, Michael Stephen Moores, Notary Public, personally appeared Julie Cherrington, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Michael Stephen Moores (Seal)



TABLE 1

Docket No.	Country	Serial No.	Filed	Title
322610-888003 (12633-003-888)	U.S.	61/164,359	03/27/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
322610-888006 (12633-006-888)	U.S.	61/223,687	07/07/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
322610-888008 (12633-008-888)	U.S.	61/247,454	09/30/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
322610-036008 (12633-008-036)	AR	10 01 00996	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
322610-185008 (12633-008-185)	TW	099109225	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
322610-228008 (12633-008-228)	PCT	PCT/NZ2010/000060	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
322610-999008 (12633-008-999)	U.S.	12/748,251	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
322610-888004 (12633-004-888)	U.S.	61/164,358	03/27/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-228004 (12633-004-228)	PCT	PCT/NZ2010/000061	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-888005 (12633-005-888)	U.S.	61/223,684	07/07/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-888007 (12633-007-888)	U.S.	61/247,448	09/30/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-888009 (12633-009-888)	U.S.	61/318,195	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-036009 (12633-009-036)	AR	P100102428	07/06/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-185009 (12633-009-185)	TW	099122213	07/06/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-228009 (12633-009-228)	PCT	PCT/NZ2010/000139	07/06/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-999009 (12633-009-999)	U.S.	12/831,128	07/06/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
322610-888010 (12633-010-888)	U.S.	61/387,836	09/29/10	1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy